Glenmark says FabiFlu reduces viral load by 4 days, treats mild to moderate COVID-19 patients
Business | June 22, 2020 12:28 ISTGlenmark has become the first pharmaceutical company in India to receive regulatory approval for oral antiviral favipiravir, for the treatment of mild to moderate COVID-19.